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LETTERS TO THE EDITOR
Regarding “Meta-analysis of femoropopliteal bypass
grafts for lower extremity arterial insufficiency”
According to a recent meta-analysis of uncontrolled series
by Pereira et al (J Vasc Surg 2006;44:510-7), saphenous vein
grafts performed better than polytetrafluoroethylene (PTFE)
grafts in above-knee femoropopliteal bypass. The best evidence
that a treatment surpasses another, however, should come from
a meta-analysis of randomized controlled trials (RCTs). When
only RCTs in a systematic review of above-knee femoropopliteal
bypass by Klinkert et al1 (published in 2004) were considered,
the patency of saphenous vein grafts was better than that for
PTFE grafts. The analysis included four RCTs by Veith et al,2
AbuRahma et al,3 Johnson and Lee,4 and Burger et al.5 After the
inclusion period (from 1966 to 2002) of the review by Klinkert
et al,1 to our knowledge, Klinkert et al6 updated the 2-year
outcomes of the RCT by Burger et al,5 and Ballotta et al7
reported the results of another RCT. Although a bypass with
saphenous vein grafts had better patency in the RCT by Klinkert
et al,6 saphenous vein and PTFE grafts had a statistically com-
parable patency in the RCT by Ballotta et al.7 To test the
hypothesis that saphenous vein and PTFE grafts are equally
beneficial in above-knee femoropopliteal bypass, we performed
a meta-analysis of currently available RCTs of saphenous vein vs
PTFE grafts in above-knee femoropopliteal bypass.
Our comprehensive search identified 5 RCTs2-6 that in-
cluded 395 saphenous vein and 435 PTFE grafts. We analyzed
the primary patency of three RCTs2,3,5 and the primary assisted
patency of two RCTs4,6 because these two RCTs did not report
primary patency. The pooled primary graft patency of saphe-
nous vein and PTFE grafts was 86.6% and 83.7% at 1 year,
82.6% and 74.6% at 2 years, 79.2% and 65.3% at 3 years, 77.6%
and 61.3% at 4 years, and 76.4% and 56.1% at 5 years, respec-
tively (Fig). Risk ratios ( 1, favors PTFE grafts;  1, favors
saphenous vein grafts) for graft occlusion pooled by using a
random-effects model were 1.13 (confidence interval, 0.85-
1.52; P  .3957) at 1 year, 1.34 (confidence interval, 1.05-
1.70; P  .0198) at 2 years, 1.44 (confidence interval, 1.16-1.80;
P  .0011) at 3 years, 1.52 (confidence interval, 1.23-1.87; P 
.0001) at 4 years, and 1.68 (confidence interval, 1.34-2.11; P 
.0001) at 5 years. There was neither between-study heterogeneity
nor publication bias.
The best evidence on the basis of the present meta-analysis of
RCTs demonstrated that saphenous vein grafts were superior to
PTFE grafts in above-knee femoropopliteal bypass, thus supporting
the conclusions of the meta-analysis of uncontrolled series by Pereira
et al.
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Reply
We agree with Dr Takagi that a meta-analysis of randomized
controlled trials provides the best scientific evidence. However,
they are scarce in the literature.
Meta-analysis of uncontrolled surgical series may give a reliable
account of available data because these series are frequent in the
literature and often involve a larger number of patients. The larger
numbers of series and patients pooled in our studymade it possible to
separate them according to grades of ischemia of the limb (meta-
analysis I and II) and primary and secondary patencies with at least 10
series in eachgroup.Thedivision according to grades of limb ischemia
allowed us to observe that the difference between saphenous vein and
PTFE patency rates were even greater in patients with critical isch-
emia.
Conversely, Takagi’s article polled only three and two studies,
respectively, for primary and secondary patency rates. Anyway, we
are glad his group achieved the same results as we did.
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Fig. Meta-analysis of primary patency for above-knee femoropop-
liteal saphenous vein (SV; black line) and polytetrafluoroethylene
(PTFE; gray line) bypass grafts.
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